Biotech
Upstream Bio
Upstream Bio raises $153M Series B at $800M valuation
$153M
Total Raised
Series B
Latest Round
2020
Founded
120+
Employees
Waltham, MA
1 min read
Quick Facts
Valuation
$800M
Latest Round Size
$153M
Latest Round Date
September 2024
Upstream Bio: Series B Funding Round
Upstream Bio has successfully raised $153M in Series B funding, reaching a valuation of $800M.
Company Overview
Developing antibody therapeutics for inflammatory diseases
Funding Details
The Series B round was led by Fidelity, with participation from Viking Global.
Company Information
- Headquarters: Waltham, MA
- Founded: 2020
- Employees: 120+
- Category: Biotech
Investment
Upstream Bio plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Fidelity: Verified investor in Series B
- Viking Global: Verified investor in Series B
Key Investors
Fidelity
Lead Investor
Verified investor in Series B
Viking Global
Investor
Verified investor in Series B
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M